China’s cosmetics market hit USD 85 billion in 2025, and regulators have not slowed down. Since the 2019 ban on “medical cosmetics” claims, the rules have tightened year after year. In 2026, foreign beauty brands face a market that rewards compliance and punishes shortcuts. The NMPA (National Medical Products Administration, the successor to CFDA) now enforces registration requirements, ingredient transparency, and advertising standards that catch many Western brands off guard. If you are entering China or scaling your presence here, you need to understand the regulatory terrain before you spend a dollar on marketing.
The 2019 Ban and What Changed After
In February 2019, China made it illegal to use terms like “medical cosmetics” (医美化妆品) or “medical care product” on packaging, in ads, or across digital platforms. The rule targeted a grey zone that had grown massively: products marketed as having pharmaceutical-grade benefits without going through drug registration.
The reaction was immediate. Taobao pulled listings using those terms within weeks. NetEase Kaola and Vip.com followed. Brands like Vichy and La Roche Posay rewrote their Chinese-language product pages. It was a real reset for the dermo-cosmetic category.
What came next was stricter. The Cosmetics Supervision and Administration Regulation (CSAR), which took full effect in January 2022, introduced:
- A two-tier system: “ordinary” cosmetics vs. “special use” cosmetics (whitening, hair dye, sunscreen, anti-hair loss, etc.)
- Mandatory registration for all special-use products before they can be sold
- Full ingredient disclosure requirements
- Responsible Person (RP) obligations for all imported brands
- Stricter efficacy claim substantiation: you must have clinical or lab data to back any claim
By 2024, the NMPA had rejected thousands of registrations and issued public warnings against brands making unsubstantiated anti-aging, brightening, or repair claims. In 2025-2026, enforcement has moved from registration to post-market surveillance, meaning brands already on shelves are now being audited.
The 2026 Regulatory Environment: Key Rules You Cannot Ignore
Here is where things stand in 2026:
Efficacy claim rules are enforced strictly. You cannot say a product “repairs the skin barrier” without clinical evidence filed with the NMPA. Vague claims like “revitalizing” or “restoring youth” are flagged during registration and in advertising audits. The NMPA published an updated Efficacy Claims Classification List in 2023 that brands must follow exactly.
New ingredient registration requirements. Any cosmetic ingredient not on China’s Inventory of Existing Cosmetic Ingredients (IECIC) requires a new ingredient notification or registration. This process takes 3 to 6 months minimum. Brands launching products with novel peptides, botanical extracts, or biotech actives must plan well ahead.
Live-stream advertising is regulated. Since 2023, the CAC and market regulators require that all claims made during live-stream sales (Douyin, Taobao Live, Xiaohongshu) match the registered product dossier. KOL scripts are now legally the brand’s responsibility. A KOL overstating product results can trigger fines against the brand, not just the influencer.
Cross-border e-commerce (CBEC) is not a regulatory shortcut. Many brands tried to use Tmall Global or JD Worldwide to avoid full registration. In 2026, CBEC products still need to comply with advertising standards and ingredient disclosure. The NMPA has signaled it will apply the same efficacy claim rules to CBEC cosmetics by the end of 2026.
French brands like Avene, Bioderma, and Uriage have managed the transition well. They invested in proper NMPA registration, removed clinical-sounding language from Chinese packaging, and shifted their messaging to skin science and formulation transparency. That approach works.
How the Market Has Shifted: Consumer Behavior in 2026
China’s skincare segment still represents around 40% of the total cosmetics market, above the global average of roughly 28%. But consumer preferences have shifted toward what Chinese consumers call “成分党” (chéng fèn dǎng), or “ingredient faction”, buyers who research actives, concentrations, and clinical evidence before purchasing.
This trend plays directly into the regulatory push for transparency. Brands that can explain their formulas, cite studies, and demonstrate results through third-party testing are winning on Xiaohongshu and Douyin. Brands that rely on vague luxury imagery are losing ground.
Key 2026 market data:
- China’s cosmetics market: USD 85 billion (2025), growing at approximately 8-10% annually
- Online sales (e-commerce + CBEC): now represent over 45% of cosmetics revenue
- Xiaohongshu has over 300 million monthly active users, with beauty as the top content category
- Douyin beauty GMV exceeded RMB 200 billion in 2024
- Domestic brands (C-beauty) now hold roughly 38% of the mass market, up from 25% in 2019
The rise of C-beauty brands like Proya, Florasis, and Winona puts real pressure on imported brands. Winona in particular built its entire positioning around sensitive skin claims, backed by clinical data filed with the NMPA. That is the standard foreign brands now compete against.
How to Market Cosmetics in China Without Breaking the Rules
Compliance does not mean boring marketing. Here is what works in 2026:
Build credibility through ingredient transparency. Publish your key actives, concentrations (where possible), and formulation philosophy. Chinese consumers cross-reference this on ingredient apps like INCI Decoder and Cosdna. If your formula is good, show it.
Use dermatologist and lab endorsements properly. You can reference dermatological testing and clinical studies, as long as you have the data to back it up and it aligns with your NMPA registration. This is different from calling your product a “medical cosmetic.”
Work with KOLs who understand compliance. The era of giving influencers total freedom to make claims is over. Brief your KOLs with approved talking points. Have a legal or compliance review before any major campaign goes live on Douyin or Xiaohongshu.
Invest in consumer education content. Long-form skincare education on WeChat builds trust. Ingredient explainers, skin type guides, and honest product comparisons perform well and stay within legal boundaries.
Plan your registration timeline realistically. Special-use cosmetic registration takes 6 to 12 months. Ordinary cosmetics filing takes 1 to 3 months. Build this into your launch plan, not as an afterthought.
See our full guide on cosmetics marketing in China for channel-by-channel strategy.
Olivier Verot’s View
I have watched brands come into China with great products and fall apart because they underestimated the regulatory process. The 2019 ban on medical cosmetics claims was a warning shot. The 2022 CSAR was a full restructuring. And now in 2026, post-market enforcement is real. The NMPA is not just checking registrations, it is auditing live-stream scripts and flagging WeChat articles.
The brands that win in China right now are not the ones with the biggest budgets. They are the ones that do the compliance work first, then build their marketing on solid ground. La Roche Posay adapted well. Bioderma adapted well. They removed the quasi-medical language, invested in proper clinical substantiation, and leaned into the ingredient-educated consumer trend. That combination works.
Foreign brands still have a real advantage in China: heritage, formulation credibility, and the perception of European or American scientific rigor. But that advantage disappears the moment you make a claim you cannot back up. One NMPA warning letter, one viral exposure on social media calling out false advertising, and two years of brand-building evaporates. Do the work upfront. Register properly. Brief your KOLs correctly. The market rewards it.
4 Mistakes Foreign Beauty Brands Make in China
- Using the same claims as in Western markets. “Clinically proven to reduce wrinkles by 40%” might be acceptable in France or the US. In China, that claim triggers scrutiny. You need the specific clinical data filed with your NMPA registration, not just a reference to a study done elsewhere.
- Treating CBEC as a permanent workaround. Cross-border e-commerce was genuinely easier for years. Now the NMPA is closing gaps. Brands that built their entire China strategy on Tmall Global without registration are exposed as 2026 enforcement extends to CBEC channels.
- Briefing KOLs with zero compliance oversight. A single Xiaohongshu post where a KOL calls your moisturizer “better than a hospital treatment” can create legal liability. Brand teams must review influencer content against registered claims before publication, every time.
- Ignoring C-beauty competition. Domestic brands now match or exceed international brands on formulation sophistication, they move faster, they cost less, and they speak to Chinese consumers in a way that feels native. If your China strategy is the same as it was in 2020, it will not work in 2026.
5 Questions About China Cosmetics Regulations from Chinese Consumers
Q: 医美产品和普通护肤品有什么区别？(What is the difference between medical cosmetics and regular skincare?)
A: Medical cosmetics (医疗美容) are procedures or products classified as medical devices and regulated by the NMPA as drugs. Regular skincare is regulated as cosmetics. Since 2019, you cannot call a cosmetic a “medical cosmetic” even if it has active ingredients. The line is about regulatory classification, not ingredient strength.
Q: 外国品牌的产品在中国安全吗？(Are foreign brand products safe in China?)
A: Imported cosmetics sold through official channels, either registered with the NMPA or sold via licensed CBEC platforms, go through ingredient and safety checks. The risk comes from parallel imports or unofficial resellers who sell products without registration. Buy from official brand stores or authorized retailers.
Q: 品牌可以在中国宣称产品有美白效果吗？(Can brands claim whitening effects in China?)
A: Yes, but whitening is classified as a “special use” function under the CSAR. The brand must register the product specifically as a whitening cosmetic and submit clinical evidence. A brand cannot casually add “brightening” claims to a product registered as an ordinary moisturizer.
Q: 我在小红书上看到的护肤品功效都是真的吗？(Are the skincare benefits I see on Xiaohongshu real?)
A: Not always. Regulations require that KOL claims match registered product functions, but enforcement is imperfect. Look for posts that reference specific actives and concentrations rather than vague “miracle” results. Brands with NMPA registration and published ingredient lists are a safer bet.
Q: 直播中夸大产品效果违法吗？(Is it illegal to exaggerate product effects during live-streams?)
A: Yes. Since 2023, advertising law applies fully to live-stream commerce. If a KOL or brand representative makes a claim during a Douyin or Taobao Live session that is not backed by registered data, both the influencer and the brand can face fines. The brand is legally responsible for ensuring the script stays within approved claims.
Sources
- NMPA (National Medical Products Administration) official portal
- Statista: Cosmetics Industry in China
If you are launching or scaling a cosmetics brand in China in 2026, the regulatory environment is not optional reading. Your registration strategy, your KOL briefs, and your product claims all have to align. We help brands get this right before they enter the market, not after the first compliance issue. Get a free social media audit for your brand in China
